` SOM (Somnomed Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

SOM
vs
S&P/ASX 300

Over the past 12 months, SOM has significantly outperformed S&P/ASX 300, delivering a return of 105% compared to the S&P/ASX 300's 2% growth.

Stocks Performance
SOM vs S&P/ASX 300

Loading

Performance Gap
SOM vs S&P/ASX 300

Loading
SOM
S&P/ASX 300
Difference

Performance By Year
SOM vs S&P/ASX 300

Loading
SOM
S&P/ASX 300
Add Stock

Competitors Performance
Somnomed Ltd vs Peers

S&P/ASX 300
SOM
ABT
ISRG
BSX
SYK
Add Stock

Somnomed Ltd
Glance View

Market Cap
95.1m AUD
Industry
Health Care

SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.

SOM Intrinsic Value
0.57 AUD
Undervaluation 23%
Intrinsic Value
Price
Back to Top